A clinical trial conducted in the midst of an Ebola epidemic in the Democratic Republic of Congo (DRC) has identified two new drugs that can dramatically cut mortality from the disease, and both are being immediately offered to all patients in an effort to control the country’s worst ever outbreak.
The Pamoja Tulinde Maisha (“together save lives” in Swahili) trial began last November, in four towns stricken by the outbreak. It compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3.
Preliminary data has convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.1
Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was not far behind. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.
Patients treated with ZMapp, the best known Ebola treatment candidate, which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate.
More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.
Researchers believe they can improve outcomes further in patients who are reached early in the course of infection. Among such patients, mortality rates were 6% with REGN-EB3, 11% with mAb114, 24% with ZMapp, and 33% with remdesivir.
Both REGN-EB3 and mAb114, like ZMapp, are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells.
Regeneron Pharmaceuticals made REGN-EB3, a cocktail of three such proteins, using antibodies from “humanised” mice infected with Ebola.
The US National Institute of Allergy and Infectious Diseases created mAb114 using antibodies isolated from the blood of a survivor of a 1995 outbreak in DRC. It will be developed by Ridgeback Therapeutics.
“From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe-Tamfum, director of the DRC’s Institut National de Recherche Biomédicale, which oversaw the trial. Full results are expected by early October and will appear in a peer reviewed journal soon thereafter.
Muyembe, who was part of the team that discovered the Ebola virus 43 years ago, and who in 1995 became the first doctor to harvest antibodies from survivors, told a press conference that the news of effective treatments would reinvigorate the campaign to end the current outbreak, which has struggled against deep local suspicion in a region plagued by insecurity.
“People think that if you enter a treatment centre, you’ll leave in a coffin,” said Muyembe. But with such high survival rates in the newly infected, he said, “We have a great message: a treatment centre is a place where you can recover and that you leave alive.”
The Latest on: Ebola
via Google News
The Latest on: Ebola
- CDC Implements Travel Restrictions for Countries With Ebola Caseson March 1, 2021 at 1:16 pm
The (CDC) announced on Friday that it's taking swift action to prevent the spread of the recent Ebola outbreak in two African countries by implementing new travel restrictions. Starting this week, ...
- US issues public health measures for DRC, Guinea travelers fearing ebolaon March 1, 2021 at 1:10 pm
WASHINGTON - The Centers for Disease Control and Prevention (CDC) will impose new public health requirements for US visitors who have recently been in the Democratic Republic of the Congo (DRC) or ...
- Three new Ebola cases confirmed in Congo, two in Guineaon March 1, 2021 at 9:59 am
Three new cases of Ebola have been confirmed in eastern Democratic Republic of Congo, bringing to 11 the number of cases since authorities declared a resurgence of the virus last month. In a ...
- CDC announces Ebola travel restrictions: Passengers from Congo, Guinea will be funneled to six airportson March 1, 2021 at 6:15 am
Airline passengers arriving from the Democratic Republic of Congo and Guinea will be routed to certain airports starting in early March.
- Start your week smart: Stimulus bill, coronavirus, QAnon, school raid, Ebolaon February 28, 2021 at 6:34 am
Here's what else you need to know to Start Your Week Smart. The FDA authorized the third coronavirus vaccine in the US and the first one available as a single dose. US federal health officials ...
- Exclusive: White House orders enhanced airport screenings for Ebolaon February 27, 2021 at 4:32 pm
The Biden administration is moving forward with plans to screen airline passengers from two African countries arriving in the U.S. for Ebola, which will involve sending them to one of about a half ...
- U.S. implements travel restrictions for DRC, Guinea amid Ebola outbreakson February 27, 2021 at 8:24 am
The U.S. government is implementing new measures to prevent the spread of the Ebola virus by travelers from Guinea and the Democratic Republic of Congo entering the country ...
- The CDC says the US will screen and track people traveling from countries with Ebola caseson February 27, 2021 at 8:01 am
Travelers coming in from the Democratic Republic of Congo and Guinea will have their info sent to local health departments for tracking purposes.
- CDC announces travel restrictions for countries hit by Ebolaon February 27, 2021 at 3:19 am
Travel precautions will be imposed for individuals coming to the US from Guinea and the Democratic Republic of Congo -- two countries fighting recent outbreaks of the Ebola virus, the US Centers for ...
- U.S. to implement Ebola monitoring program at airportson February 26, 2021 at 9:50 pm
Starting next week, the "very small number" of travelers arriving from Guinea and the Democratic Republic of the Congo will be funneled to six U.S. airports, the CDC said.
via Bing News